NEWS
News Articles
Billions will not receive a COVID-19 vaccine in 2021
New York, NY, January 12, 2021 — As high-income countries begin to roll out COVID-19 vaccination campaigns, there are increased concerns that billions of people will not receive the vaccine, putting the global community at risk of prolonging this pandemic and its devastating knock-on effects. Shortages in supply of COVID-19 vaccines, coupled with vaccine nationalism, means the…
Read MoreGeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development
Company Focused on Single-dose Vaccine Against Multiple COVID Strains ATLANTA, GA, January 11, 2021 – GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the…
Read MoreMaria Thacker-Goethe, Georgia Bio President and CEO, Named to “100 Most Influential Georgians” list by Georgia Trend Magazine
Atlanta, Georgia (January 11, 2021) – Georgia Bio, the state’s public policy and business solutions organization representing Georgia’s life sciences sector, announced today that President and CEO Maria Thacker-Goethe was named to Georgia Trend magazine’s “100 Most Influential Georgians” list for 2021. “It is an incredible honor to be chosen amongst such esteemed colleagues,” said…
Read MoreWall Street analysts are cautiously optimistic on J&J’s ‘one-dose’ Covid vaccine
LONDON — Health care systems around the world are struggling to cope with rising numbers of Covid-19 infections as they race against the clock to vaccinate the vulnerable. The three vaccines currently approved for use by major Western economies all require two separate jabs and given supplies are limited, governments are considering contentious tactics like stretching…
Read MoreSanofi Ups Immunology Game With $1.4 Billion Acquisition of Kymab
French pharma giant Sanofi kicks off 2021 with a $1.4 billion cash acquisition of U.K.-based Kymab to bolster the company’s presence in immunology. The deal adds Kymab’s lead asset KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L. It is thought that KY1005 has the potential to treat a wide variety of…
Read MoreAfter Covid-19 success, Moderna is going after an HIV vaccine
Arguably the most important outcome of the Covid-19 vaccines produced by Pfizer and Moderna isn’t ending the pandemic. Instead, it’s what the innovative mRNA technology used to make the vaccine could do next. Vaccines using mRNA have potential uses far beyond immunization—to treat cancer, for instance, or addiction, Lynda Stuart, deputy director for vaccines at the Bill and…
Read More